SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentGlobeNewsWire • 03/25/24
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/08/24
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewsWire • 01/23/24
Here's Why SAB Biotherapeutics, Inc. (SABS) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 12/08/23
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesGlobeNewsWire • 11/29/23
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 DiabetesGlobeNewsWire • 11/14/23
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesGlobeNewsWire • 11/14/23
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesGlobeNewsWire • 10/19/23
SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of DirectorsGlobeNewsWire • 10/05/23
SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 DiabetesGlobeNewsWire • 10/02/23
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023GlobeNewsWire • 06/21/23
SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International ConventionGlobeNewsWire • 05/30/23
SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy InnovationsGlobeNewsWire • 05/19/23